2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|September 2, 2004
- Pharmaceutical Technology-09-02-2004
- Volume 28
- Issue 9
Excel file and formula for Determining Probability of Passing the USP Content Uniformity Test
Excel File
Advertisement
Articles in this issue
about 22 years ago
In the Spotlight-September 2004about 22 years ago
Promoting Quality in Drug Manufacturingabout 22 years ago
Automation in a Digital, Webbed, and Wireless Ageabout 22 years ago
September 2004about 22 years ago
Design of an Aseptic Process Simulationabout 22 years ago
Early Development Still Driving CRO Performanceabout 22 years ago
Particulate-Free PalletsAdvertisement
Related to this article
On PharmTech.com this week, coverage of upcoming events continued, experts continued to discuss the use of AI in pharma, and validation in oral solid dosage product production was emphasized.
This week saw predictive modeling, microstructure intelligence, a CAR T-cell safety pause, and major licensing deals reshape pharma manufacturing.
Robert Holt, PhD, associate director, Pharmaceutical Science, digiM Solution, discusses microstructure intelligence in more detail in part 2 of this preview of the company’s keynote presentation at AAPS PharmSci 360.
The finalists for the 2026 CPHI Pharma Awards span 15 categories including API development, digital transformation, manufacturing, supply chain, sustainability, and leadership, with winners revealed October 6 at CPHI Milan.
In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.
This week’s PharmTech.com content covered AI agent authority, hold-time and nitrosamine risk frameworks, biologics formulation, 3D bioprinting, and major oncology and dealmaking news.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Driving Quality Culture to Manage Risk: Lessons from an FDA Inspection Response
2
Mature Medicines Divestment Signals Shift in Manufacturing Strategy
3
FDA's IND Pilot Puts CMC Review First
4
Successful Internal Audit Planning and Execution
5